Tech and healthcare help European shares above one-month highs



(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window)

* STOXX 600 set to end 2021 21.7% higher, fell 4% in 2020

* CNH Industrial hits record high

* Defensives lead gains

* Roche up after approval for COVID-19 products (Updates with closing prices)

By Anisha Sircar

Dec 27 (Reuters) - European shares ended higher in thin trading on Monday, led by gains in technology and healthcare stocks, with Roche rising on regulatory approval for COVID-19-related products.

The pan-European STOXX 600 .STOXX rose 0.7% with technology shares .SX8P and defensive sectors like healthcare .SXDP and construction .SXOP leading gains.

The technology sub-index is on-track to be the top performer among European sectors in 2021 and is set to gain around 33%, followed by banking shares .SX7P .

Markets globally also inched higher in thin trading with the S&P 500 .SPX hitting record highs over easing concerns of the Omicron coronavirus variant.

Following a 4% drop in 2020, the STOXX 600 is on course for a 21.7% jump this year after encouraging study results on the Omicron variant drove gains last week.

"Low volume and no new surprising headlines usually allow asset prices to follow the prevailing path of least resistance," Charalambos Pissouros, head of research at JFD Group, said.

Still, the high transmissibility of the new variant remains a concern, with rising cases worldwide threatening recovery.

France hit another COVID-19 infection record on Friday, while airlines around the world cancelled more than 4,500 flights over the weekend and China reported its highest daily rise in local infections in 21 months.

"Most nations may prefer not to tighten restrictions further this week in order not to spoil the holidays, but this could be the case early next year," Pissouros said.

Among individual stocks, high-tech industrial group Groupe Gorgé GOEG.PA jumped 6.4% after confirming an indicative offer for its acquisition of iXblue.

Roche ROG.S added 0.9% after Swiss drugs regulator Swissmedic approved Ronapreve, an antibody treatment jointly developed with Regeneron REGN.O to treat COVID-19 patients.

On Friday, the U.S. Food and Drug Administration granted emergency use authorization to Roche's COVID-19 at-home rapid test that can be used by people as young as 14.

CNH Industrial CNHI.MI extended a three-day rally, adding 2.5% to hit a record high after on Thursday approving the spin-off of its truck-making business, Iveco.

British, Australian and Hong Kong markets were closed for holidays.
Reporting by Anisha Sircar, Susan Mathew and Shashank Nayar in Bengaluru; Editing by Devika Syamnath and Alexander Smith

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

我們運用 cookies 提供您最佳之網頁使用經驗。更改您的cookie 設定跟詳情。

風險提示:您的資金存在風險。槓桿商品並不適合所有客戶。請詳細閱讀我們的風險聲明